We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cassava Sciences, Inc. (SAVA) Stock Moves -1.76%: What You Should Know
Read MoreHide Full Article
Cassava Sciences, Inc. (SAVA - Free Report) closed at $43.07 in the latest trading session, marking a -1.76% move from the prior day. This move was narrower than the S&P 500's daily loss of 2.11%. Meanwhile, the Dow lost 1.54%, and the Nasdaq, a tech-heavy index, lost 0.3%.
Heading into today, shares of the company had gained 70.39% over the past month, outpacing the Medical sector's loss of 4.04% and the S&P 500's loss of 8.19% in that time.
Investors will be hoping for strength from Cassava Sciences, Inc. as it approaches its next earnings release. In that report, analysts expect Cassava Sciences, Inc. to post earnings of -$0.47 per share. This would mark a year-over-year decline of 95.83%.
Any recent changes to analyst estimates for Cassava Sciences, Inc. should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Cassava Sciences, Inc. currently has a Zacks Rank of #4 (Sell).
The Medical - Drugs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 81, which puts it in the top 33% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow SAVA in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Cassava Sciences, Inc. (SAVA) Stock Moves -1.76%: What You Should Know
Cassava Sciences, Inc. (SAVA - Free Report) closed at $43.07 in the latest trading session, marking a -1.76% move from the prior day. This move was narrower than the S&P 500's daily loss of 2.11%. Meanwhile, the Dow lost 1.54%, and the Nasdaq, a tech-heavy index, lost 0.3%.
Heading into today, shares of the company had gained 70.39% over the past month, outpacing the Medical sector's loss of 4.04% and the S&P 500's loss of 8.19% in that time.
Investors will be hoping for strength from Cassava Sciences, Inc. as it approaches its next earnings release. In that report, analysts expect Cassava Sciences, Inc. to post earnings of -$0.47 per share. This would mark a year-over-year decline of 95.83%.
Any recent changes to analyst estimates for Cassava Sciences, Inc. should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Cassava Sciences, Inc. currently has a Zacks Rank of #4 (Sell).
The Medical - Drugs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 81, which puts it in the top 33% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow SAVA in the coming trading sessions, be sure to utilize Zacks.com.